Tohoku University Venture Partners
VC Fund
Sendai-shi, Japan
Tohoku University Venture Partners is a VC fund in Sendai-shi focused on Manufacturing and Medical. THVP is a venture capital corporation for startup innovation. It was established in 2015 and is based in Nagoya, Japan.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 51%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Tohoku University Venture Partners invests in
Stages Tohoku University Venture Partners invests in
Countries Tohoku University Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $271k–$2.5M
- Series A
- $1M–$7.9M
- Venture - Series Unknown
- $459k–$8.8M
Investment Focus
Industry
- Manufacturing 11 (21%)
- Medical 10 (19%)
- Biotechnology 10 (19%)
- Health Care 9 (17%)
- Product Design 5 (9%)
Stage
- Venture - Series Unknown 16 (30%)
- Seed 11 (21%)
- Series A 11 (21%)
- Series B 5 (9%)
- Series C 3 (6%)
Country
- Japan 38 (72%)
- China 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tetsuro Higuchi
Director and President
|
Director and President | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SiccaNova Therapeutics
|
SiccaNova Therapeutics is a Japanese biopharmaceutical company dedicated to treating sicca (dryness) related medical conditions. The company’s lead drug candidate, XF8302, is a novel, small-molecule M3 muscarine receptor Positive Allosteric Modulator (M3 PAM). Developed initially for dry mouth in Sjögren’s syndrome patients, the drug enhancesnatural acetylcholine signaling to stimulate salivation without the systemic side effects common in traditional agonists. | $7.9M / Series A / Sep 03, 2026 | |
Scohia Pharma
|
Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M / May 28, 2026 | |
Koeda
|
KOEDA is researching and developing medical devices that are safe, painless, and easy to use for acute cholecystitis. KOEDA will transform the management of cholecystitis. So far, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has been a notably difficult procedure carried out by skilled doctors at specific advanced centers. Althoughinserting a tube into the gallbladder is less invasive, it is complex, and there may be concerns regarding bile leakage. By combining clinical expertise with precision engineering, KOEDA addresses a clearly defined medical need in a growing global market and is currently moving forward on schedule for regulatory clearance and commercialization. | Venture - Series Unknown / Mar 31, 2026 | |
Storyline
|
Storyline is a company that use technology and design to address social challenges while building a sustainable society. | Venture - Series Unknown / Dec 24, 2025 | |
ElevationSpace
|
ElevationSpace offers high quality & well equipped workspaces giving tenants a nurturing environment . | $7.5M / Series B / Sep 17, 2025 | |
RevolKa
|
RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1.5M / Series A / May 20, 2025 | |
Rege Nephro
|
Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $15.2M / Series B / Oct 07, 2024 | |
Hakko Holdings
|
Hakko Holdings is a food-tech company that specializes in producing and manufacturing fermented plant-based food with unique fermentation technology for healthy and sustainable lives. | Seed / Oct 04, 2024 | |
Luxna Biotech
|
Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments. | $1.7M / Series C / Sep 06, 2024 | |
|
Koeda
|
KOEDA is researching and developing medical devices that are safe, painless, and easy to use for acute cholecystitis. KOEDA will transform the management of cholecystitis. So far, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has been a notably difficult procedure carried out by skilled doctors at specific advanced centers. Althoughinserting a tube into the gallbladder is less invasive, it is complex, and there may be concerns regarding bile leakage. By combining clinical expertise with precision engineering, KOEDA addresses a clearly defined medical need in a growing global market and is currently moving forward on schedule for regulatory clearance and commercialization. | Seed / Jun 03, 2024 | |
| See all 53 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tohoku University Venture Partners invest in?
Tohoku University Venture Partners invests primarily in Manufacturing, Medical and Biotechnology startups, most often at Venture - Series Unknown and Seed stage. Most of the 53 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tohoku University Venture Partners's check size?
Tohoku University Venture Partners typically joins rounds of $271k–$2.5M at Seed, $1M–$7.9M at Series A and $459k–$8.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tohoku University Venture Partners participates in.
How do I contact Tohoku University Venture Partners?
Public channels for Tohoku University Venture Partners include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tohoku University Venture Partners?
The team at Tohoku University Venture Partners includes Tetsuro Higuchi (Director and President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
